SCHEMBL2219207

SCHEMBL2219207

COC(=O)c1ccc(COCCNC(=O)c2cc([N+](=O)[O-])cc([N+](=O)[O-])c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.57
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MAPT P10636 4/20 0.53
LMNA P02545 3/20 0.53
HTT P42858 3/20 0.52
PKM P14618 1/20 0.49
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578835 0.89 MEN1 (0.64) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL1578808 0.88 MAPT (0.57) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL2216223 0.86 MEN1 (0.54) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL1578827 0.86 SMN1; SMN2 (0.56) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL2216336 0.86 LMNA (0.66) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL1579991 0.85 MAPT (0.49) GAAKMT2AMEN1MAPTHTT
SCHEMBL1578099 0.84 MAPT (0.74) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL1578022 0.84 MAPT (0.53) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL2218076 0.81 MEN1 (0.73) GAAKMT2AMEN1L3MBTL1MAPT
SCHEMBL1578307 0.81 MAPT (0.69) GAAKMT2AMEN1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310388-B1 PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS PASTEUR INSTITUT KOREA (KR) 2015-08-05 EP disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
WO-2010003533-A2 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178077-A1 Anti-infective compounds RABGGTB, ELANE, SERPINB1 GAA 949/4885KMT2A 4781/4885MEN1 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.